Explore

Rapid Read Rapid Read
Resmetirom Shows Potential in Combating Liver Cancer Linked to Fatty Liver Disease

Resmetirom Shows Potential in Combating Liver Cancer Linked to Fatty Liver Disease

A recent study has revealed that Resmetirom, a drug approved by the U.S. Food and Drug Administration (FDA) for treating metabolic dysfunction associated fatty liver disease (MAFLD), may also help prevent and suppress liver cancer. Conducted by researchers from the University of Hong Kong, the study found that Resmetirom not only reduces liver fat but also slows tumor growth and lowers levels of the Midkine (MDK) protein, which is linked to cancer progression. The study highlights the potential of Resmetirom in reshaping the immune microenvironment and improving liver metabolism, suggesting its clinical value in future treatment strategies for liver cancer.
Trendline Trendline
FDA Clears Glooko's EndoTool IV Cloud for Hospital Insulin Dosing

FDA Clears Glooko's EndoTool IV Cloud for Hospital Insulin Dosing

FDA Clears Glooko's EndoTool IV Cloud for Hospital Insulin Dosing
Reuters Reuters
No clear autism link to antidepressant use during pregnancy, large study finds

No clear autism link to antidepressant use during pregnancy, large study finds

By Nancy Lapid May 14 (Reuters) - The use of antidepressants while pregnant does not raise the children's risk for developmental disorders such as autism, according to an analysis of data from more than 25 million pregnancies that appears to contradict assertions by U.S. Health Secretary Robert F.
Trendline Trendline
FDA Approves Inqovi and Venetoclax Combo for Acute Myeloid Leukemia

FDA Approves Inqovi and Venetoclax Combo for Acute Myeloid Leukemia

FDA Approves Inqovi and Venetoclax Combo for Acute Myeloid Leukemia
Trendline Trendline
Affinia Therapeutics Presents Promising Data for Gene Therapy in Cardiomyopathy

Affinia Therapeutics Presents Promising Data for Gene Therapy in Cardiomyopathy

Affinia Therapeutics Presents Promising Data for Gene Therapy in Cardiomyopathy
Trendline Trendline
Sun Pharma Recalls Cancer Drug Due to Glass Particle Contamination

Sun Pharma Recalls Cancer Drug Due to Glass Particle Contamination

Sun Pharma Recalls Cancer Drug Due to Glass Particle Contamination
Trendline Trendline
FDA Approves BeOne and Taiho Drugs for Blood Cancer Treatment

FDA Approves BeOne and Taiho Drugs for Blood Cancer Treatment

FDA Approves BeOne and Taiho Drugs for Blood Cancer Treatment
Reuters Reuters
WHO warns loosely regulated nicotine pouches risk youth addiction

WHO warns loosely regulated nicotine pouches risk youth addiction

By Emma Rumney LONDON, May 15 (Reuters) - The World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning that the highly addictive products were being "aggressively marketed" in ways that particularly appealed to younger people. 
Trendline Trendline
PureTech to Present Deupirfenidone Program at American Thoracic Society Conference, Aiming to Transform IPF Treatment

PureTech to Present Deupirfenidone Program at American Thoracic Society Conference, Aiming to Transform IPF Treatment

PureTech to Present Deupirfenidone Program at American Thoracic Society Conference, Aiming to Transform IPF Treatment
Trendline Trendline
Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development

Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development

Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development
Trendline Trendline
GLP-1 Drugs for Weight Loss: Benefits and Risks Explored

GLP-1 Drugs for Weight Loss: Benefits and Risks Explored

GLP-1 Drugs for Weight Loss: Benefits and Risks Explored
Rapid Read Rapid Read
Shionogi's Ensitrelvir Shows Promise in Preventing COVID-19 Post-Exposure

Shionogi's Ensitrelvir Shows Promise in Preventing COVID-19 Post-Exposure

A study published in the New England Journal of Medicine highlights the effectiveness of Shionogi's investigational oral antiviral, ensitrelvir, in preventing symptomatic COVID-19 following exposure. The Phase 3 SCORPIO-PEP study demonstrated that a five-day course of ensitrelvir reduced the risk of developing symptomatic COVID-19 by 67% compared to a placebo. The study involved 2,041 participants who were exposed to COVID-19 within their households. Ensitrelvir works by inhibiting viral replication, offering a potential new approach to preventing COVID-19. The drug is currently under review by the U.S. FDA for post-exposure prophylaxis, with a decision expected by June 16, 2026.